Reneo Pharmaceuticals Valuation
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
At this time, the company appears to be overvalued. Reneo Pharmaceuticals holds a recent Real Value of $14.48 per share. The prevailing price of the company is $18.2. Our model determines the value of Reneo Pharmaceuticals from analyzing the company fundamentals such as Shares Outstanding of 3.34 M, return on equity of -0.54, and Shares Owned By Institutions of 87.75 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Reneo Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Reneo Pharmaceuticals is based on 3 months time horizon. Increasing Reneo Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Reneo stock is determined by what a typical buyer is willing to pay for full or partial control of Reneo Pharmaceuticals. Since Reneo Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reneo Stock. However, Reneo Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.2 | Real 14.48 | Hype 18.65 |
The intrinsic value of Reneo Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Reneo Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Reneo Pharmaceuticals helps investors to forecast how Reneo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reneo Pharmaceuticals more accurately as focusing exclusively on Reneo Pharmaceuticals' fundamentals will not take into account other important factors: Reneo Pharmaceuticals Total Value Analysis
Reneo Pharmaceuticals is at this time forecasted to have valuation of (15.01 M) with market capitalization of 6.08 M, debt of 973 K, and cash on hands of 126.85 M. The negative valuation of Reneo Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Reneo Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(15.01 M) | 6.08 M | 973 K | 126.85 M |
Reneo Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Reneo is to check how much profit was generated for every dollar of assets it reports. Reneo Pharmaceuticals holds a negative application of assets of -0.34 pct., losing $0.003372 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Reneo Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Reneo Pharmaceuticals Ownership Allocation
The majority of Reneo Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Reneo Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Reneo Pharmaceuticals. Please pay attention to any change in the institutional holdings of Reneo Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Reneo Pharmaceuticals Profitability Analysis
Net Loss for the year was (77.39 M) with profit before overhead, payroll, taxes, and interest of 0.About Reneo Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Reneo Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Reneo Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Reneo Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Reneo Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Reneo Pharmaceuticals. We calculate exposure to Reneo Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Reneo Pharmaceuticals's related companies.Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Reneo Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Reneo Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.7 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |